KZR - ケザ―・ライフ・サイエンシズ (Kezar Life Sciences Inc.) ケザ―・ライフ・サイエンシズ

 KZRのチャート


 KZRの企業情報

symbol KZR
会社名 Kezar Life Sciences Inc (ケザ―・ライフ・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Kezar Life Sciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders cancer and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology inflammation and immune-oncology.   ケザ―・ライフ・サイエンシズは米国のバイオ医薬品企業。臨床段階で、がんおよび自己免疫疾患において満たされていない分野の新規小分子治療薬の発見・開発に従事する。同社のリ―ド製品候補であるKZRR-616は、狼そう病およびル―プス腎炎の治療に使用される。本社所在地はカリフォルニア州サウス・サンフランシスコ。   
本社所在地 4000 Shoreline Court Suite 300 South San Francisco CA 94080 USA
代表者氏名 John Fowler ジョン・ファウラー
代表者役職名 Chief Executive Officer Co-Founder
電話番号 +1 650-822-5600
設立年月日 42036
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 20人
url www.kezarlifesciences.com
nasdaq_url https://www.nasdaq.com/symbol/kzr
adr_tso
EBITDA EBITDA(百万ドル) -16.27800
終値(lastsale) 21.96
時価総額(marketcap) 419616533.16
時価総額 時価総額(百万ドル) 487.25960
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 368.87460
当期純利益 当期純利益(百万ドル) -16.10200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Kezar Life Sciences Inc revenues was not reported. Net loss increased from $4.1M to $11.7M. Higher net loss reflects Research and development - Balancing val increase from $3.2M to $8.2M (expense) General and administrative - Balancing v increase from $823K to $2.7M (expense) Stock-Based Compensation Expense increase from $37K to $617K (expense).

 KZRのテクニカル分析


 KZRのニュース

   Kezar Life Sciences (NASDAQ:KZR) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS  2021/03/13 15:34:41 Transcript Daily
Kezar Life Sciences (NASDAQ:KZR) posted its quarterly earnings data on Thursday. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01, MarketWatch Earnings reports. Shares of Kezar Life Sciences stock opened at $6.80 on Friday. The firm has a fifty day moving average of $5.76 and a […]
   Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates  2021/03/11 21:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its fourth quarter and year end 2020 financial results and corporate highlights. “Despite unprecedented circumstances, 2020 was a year of significant corporate and clinical accomplishments, thanks to the excellent execution by the Kezar team,” said John Fowler,
   Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference  2021/01/07 21:02:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference, being held on January 11-14, 2021. The presentation will be available on Monday, January 11, 2021 at 6:00am EST and may be accessed
   Kezar Life Sciences Added to the Nasdaq Biotechnology Index  2020/12/14 21:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®
   Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates  2020/11/05 21:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its third-quarter 2020 financial results and corporate highlights. “The third quarter of 2020 saw continued momentum for Kezar, punctuated by the U.S. FDA granting Orphan Drug Designations for our lead candidate KZR-616 for the treatment of polymyositis and der
   Kezar Life Sciences Inc (NASDAQ:KZR) Receives Average Recommendation of “Buy” from Analysts  2020/10/25 00:28:41 US Banking News
Kezar Life Sciences Inc (NASDAQ:KZR) has earned an average recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1-year […]
   BidaskClub Upgrades Kezar Life Sciences (NASDAQ:KZR) to “Buy”  2020/10/24 05:38:48 Dispatch Tribunal
Kezar Life Sciences (NASDAQ:KZR) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of […]
   Kezar Life Sciences (NASDAQ:KZR) Upgraded to “Buy” by BidaskClub  2020/10/23 09:56:44 Stock Observer
BidaskClub upgraded shares of Kezar Life Sciences (NASDAQ:KZR) from a hold rating to a buy rating in a research report released on Thursday, BidAskClub reports. Several other equities research analysts also recently issued reports on KZR. HC Wainwright reissued a buy rating and set a $12.00 price objective on shares of Kezar Life Sciences in […]
   Kezar Life Sciences (NASDAQ:KZR) and Heron Therapeutics (NASDAQ:HRTX) Financial Comparison  2020/10/21 08:16:41 Dakota Financial News
Kezar Life Sciences (NASDAQ:KZR) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations. Analyst Ratings This is a breakdown of recent ratings for Kezar Life Sciences and […]
   Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences  2020/10/15 11:00:00 Business Wire
SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced six presentations during four upcoming medical and scientific conferences. “The growing body of data around KZR-616, our first-in-class selective immunoproteasome inhibitor, support its unique and powerful immunomodulatory mechanism to tackle severe immune-mediated diseases
   Kezar Life Sciences (NASDAQ:KZR) and Heron Therapeutics (NASDAQ:HRTX) Financial Comparison  2020/10/21 08:16:41 Dakota Financial News
Kezar Life Sciences (NASDAQ:KZR) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations. Analyst Ratings This is a breakdown of recent ratings for Kezar Life Sciences and […]
   Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences  2020/10/15 11:00:00 Business Wire
SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced six presentations during four upcoming medical and scientific conferences. “The growing body of data around KZR-616, our first-in-class selective immunoproteasome inhibitor, support its unique and powerful immunomodulatory mechanism to tackle severe immune-mediated diseases
   Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology  2020/09/17 20:01:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted data from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and early efficacy signals of KZR-616 in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) at the Pan-American Congress of Rheumatology (PANLAR 2020
   Kezar Life Sciences to Participate in Upcoming Virtual Investor Conferences  2020/09/03 20:26:00 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences. The details of the presentations are as follows: Wells Fargo 2020 Virtual Biotech Conference Fireside Chat: Thursday, September 10, 2020, 1:20pm EDT Presenter
   Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update  2020/08/05 20:01:00 Business Wire
SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2020 financial results and corporate highlights. “Our excitement continues to build around the novel mechanism of KZR-616 and supports our conviction that targeting master regulators of cellular function – like the immunoproteasome – can benefit patients i

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ケザ―・ライフ・サイエンシズ KZR Kezar Life Sciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)